Policy brief: New TB vaccines needed to tackle AMR
Developing new TB vaccines by 2030 is within reach if decision-makers prioritize TB vaccine R&D as a signature piece of global health and AMR agendas.
The TB Vaccine Advocacy Roadmap (TB Vax ARM) released a policy brief elaborating on the urgent need of developing new TB vaccines to tackle antimicrobial resistance (AMR).
"Vaccines that prevent TB disease would save millions of lives, avert billions of dollars in treatment costs, and help curb the threat of AMR."
Access the policy brief here.
The TB Vaccine Advocacy Roadmap (TB Vax ARM) represents a global coalition of TB stakeholders, including TB survivors, civil society organizations, and non-profits, invested in TB vaccine advocacy and research.
